MA42341B2 - Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale - Google Patents

Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Info

Publication number
MA42341B2
MA42341B2 MA42341A MA42341A MA42341B2 MA 42341 B2 MA42341 B2 MA 42341B2 MA 42341 A MA42341 A MA 42341A MA 42341 A MA42341 A MA 42341A MA 42341 B2 MA42341 B2 MA 42341B2
Authority
MA
Morocco
Prior art keywords
preparation
protein kinase
kinase inhibitor
medical use
mesomer
Prior art date
Application number
MA42341A
Other languages
English (en)
Other versions
MA42341A1 (fr
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan&Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42341(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan&Lee Pharmaceuticals filed Critical Gan&Lee Pharmaceuticals
Publication of MA42341A1 publication Critical patent/MA42341A1/fr
Publication of MA42341B2 publication Critical patent/MA42341B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés tels que représentés dans la formule i ou un tautomère, un mésomère, un racémate, un énantiomère, un diastéréoisomère, un composé deutéré, un promédicament ou un mélange de ceux-ci, ou un sel ou un solvate pharmaceutiquement acceptable des composés tels que représentés dans la formule i ou un tautomère, un mésomère, un racémate, un énantiomère, un diastéréoisomère, un composé deutéré, un promédicament ou un mélange de ceux-ci, les r1 à r7 étant tels que définis
MA42341A 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale MA42341B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Publications (2)

Publication Number Publication Date
MA42341A1 MA42341A1 (fr) 2018-06-29
MA42341B2 true MA42341B2 (fr) 2021-05-31

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42341A MA42341B2 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Country Status (21)

Country Link
US (2) US11091476B2 (fr)
EP (1) EP3385262B1 (fr)
JP (2) JP6921101B2 (fr)
KR (1) KR20180083421A (fr)
CN (3) CN106810536A (fr)
AU (1) AU2016365366B2 (fr)
BR (1) BR112018010879A2 (fr)
CA (1) CA3002884A1 (fr)
CO (1) CO2018005854A2 (fr)
DK (1) DK3385262T3 (fr)
ES (1) ES2928169T3 (fr)
HU (1) HUE060152T2 (fr)
IL (1) IL259711B (fr)
MA (1) MA42341B2 (fr)
MX (1) MX387207B (fr)
PH (1) PH12018550049A1 (fr)
PT (1) PT3385262T (fr)
RU (1) RU2749437C2 (fr)
UA (1) UA124001C2 (fr)
WO (1) WO2017092635A1 (fr)
ZA (1) ZA201803531B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2019170055A1 (fr) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 Composés ayant une activité inhibitrice de kinase cdk4/6, composition pharmaceutique de ceux-ci et utilisation de ceux-ci
BR112021015004A2 (pt) * 2019-01-29 2021-10-05 Beta Pharma, Inc. Derivados de 2 h-indazol como agentes terapêuticos para cânceres cerebrais e metastases cerebrais
WO2020253865A1 (fr) 2019-06-21 2020-12-24 甘李药业股份有限公司 Procédés de préparation d'un inhibiteur de cdk4/6 et sel et intermédiaire de celui-ci
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
WO2022042738A1 (fr) * 2020-08-31 2022-03-03 甘李药业股份有限公司 Composition pharmaceutique contenant un inhibiteur de cdk4/6
US11685744B2 (en) * 2020-09-21 2023-06-27 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
CA3205652A1 (fr) 2020-12-18 2022-06-23 Prelude Therapeutics Incorporated Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
WO2022218247A1 (fr) * 2021-04-12 2022-10-20 甘李药业股份有限公司 Composé deutéré en tant qu'inhibiteur de cdk4/6
WO2022242563A1 (fr) * 2021-05-17 2022-11-24 甘李药业股份有限公司 Utilisation pharmaceutique d'un inhibiteur de cdk4/6
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024051717A1 (fr) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 Composé en tant qu'inhibiteur de plk1, son procédé de préparation et son utilisation
CN119790049A (zh) * 2022-09-30 2025-04-08 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
DE60303009T2 (de) * 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
WO2005076854A2 (fr) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Nouveaux composes chimiques
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2008124085A2 (fr) * 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2009017838A2 (fr) 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009103032A1 (fr) * 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Composés de pyrimidine-2-amine et leur utilisation en tant qu’inhibiteurs des kinases jak
BRPI0912564A2 (pt) 2008-05-16 2019-09-24 F. Hoffman-La Roche Ag inibidores de jnk
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
US10538530B2 (en) 2017-09-05 2020-01-21 Blackthorn Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
WO2022218247A1 (fr) 2021-04-12 2022-10-20 甘李药业股份有限公司 Composé deutéré en tant qu'inhibiteur de cdk4/6

Also Published As

Publication number Publication date
IL259711B (en) 2022-08-01
IL259711A (en) 2018-07-31
KR20180083421A (ko) 2018-07-20
PT3385262T (pt) 2022-10-18
ZA201803531B (en) 2021-10-27
UA124001C2 (uk) 2021-07-07
JP6921101B2 (ja) 2021-08-18
RU2018122864A (ru) 2020-01-13
EP3385262A1 (fr) 2018-10-10
MX387207B (es) 2025-03-18
CO2018005854A2 (es) 2018-06-20
RU2749437C2 (ru) 2021-06-10
RU2018122864A3 (fr) 2020-03-17
CN108290864B (zh) 2022-05-10
JP2021138737A (ja) 2021-09-16
CN113956238A (zh) 2022-01-21
US20200165239A1 (en) 2020-05-28
EP3385262A4 (fr) 2019-06-19
HUE060152T2 (hu) 2023-02-28
AU2016365366A1 (en) 2018-05-17
US20210371418A1 (en) 2021-12-02
WO2017092635A1 (fr) 2017-06-08
ES2928169T3 (es) 2022-11-15
CN108290864A (zh) 2018-07-17
PH12018550049A1 (en) 2018-10-29
CN113956238B (zh) 2023-07-14
EP3385262B1 (fr) 2022-07-13
DK3385262T3 (da) 2022-10-10
MA42341A1 (fr) 2018-06-29
BR112018010879A2 (pt) 2018-11-21
JP2019500413A (ja) 2019-01-10
CN106810536A (zh) 2017-06-09
AU2016365366B2 (en) 2021-03-04
CA3002884A1 (fr) 2017-06-08
US11787801B2 (en) 2023-10-17
MX2018006370A (es) 2018-09-24
US11091476B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA52948B1 (fr) Composés
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
MA56553B1 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA40302A1 (fr) Dérivés de carbazole
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EP3473625A4 (fr) Procédé de préparation d'un composé de pyrrolopyrimidine chiral
EP3502105A4 (fr) Forme polymorphe d'un composé inhibiteur de kinase, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
MA39983A (fr) Dérivés de carboxamide
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA50093B1 (fr) Composé pentacyclique
EP3766880A4 (fr) Forme solide d'un composé de dihydropyrimidine, son procédé de préparation et son utilisation
EP3527556A4 (fr) Procédé de préparation d'un composé d'imidazole dicétone deutéré